Oxford Outcomes Research Study
Quick Overview: Oxford Outcomes is conducting a qualitative research
study involving interviews with pheo/para patients in order to evaluate
the clarity, relevance, and comprehensiveness of two questionnaires
(one cancer specific and one pheo/para specific), and to evaluate how
effective these questionnaires are at assessing the quality of life and
symptoms of patients with pheochromocytoma or paraganglioma.
Detailed Overview and Link:
Oxford
Outcomes Inc
Molecular Insight Pharmaceuticals,
Inc. - Clinical Trial: Malignant Pheo, Paraganglioma
Quick Overview: This clinical trial benefits patients with certain
types
of pheochromocytoma, paraganglioma or metastatic carcinoid tumors.
Molecular
Insight Pharmaceuticals, Inc is located in Cambridge, MA, USA. The
actual
study is being conducted at various location. Please see the link
below for
more information about the clinical trial and locations.
Detailed Overview and Link:
Molecular
Insight
Pharmaceuticals Clinical Trials
Cornell Medical Center - Study:
Focuses on patients with symptoms of pheochromocytoma but no
evidence
of having the illness.
Quick Overview: This study benefits patients who have the severe
symptoms
that are suggestive of pheochromocytoma but who don't have evidence
to confirm
a diagnosis. Dr. Sam Mann of the New York Presbyterian Hospital in
New York
is in charge of this study.
Detailed Overview and Link:
Cornell
Medical Center Study
